Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Camrelizumab|DRUG: Nab-Paclitaxel|DRUG: Carboplatin
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Collaborators: Jiangsu HengRui Medicine Co., Ltd.